<DOC>
	<DOCNO>NCT02036489</DOCNO>
	<brief_summary>Understand dynamic elimination MRD adult patient standard-risk LAL treat pediatric protocol .</brief_summary>
	<brief_title>Pethema LAL-RI/2008 : Treatment Patients With Standard Risk Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Induction therapy administer . Patients experience slow response ( &gt; 10 % blast 15th mo treatment ) include LAL -AR -03 protocol , arm intensify induction . Those reach RC exclude study treat accord protocol LAL-AR/03 , incorporate receive block consolidation . All patient CR consolidation treatment ( 1 2 ) follow reinducciones maintenance ( maintenance -1 ) complete first year treatment maintenance without reinducciones ( maintenance -2 ) complete two year RC administer . If union persistent high level ER ( &gt; 0.05 % ) reappear late maintenance therapy patient exclude study treat accord protocol high risk ( PETHEMA LAL-AR/03 ) . In case persistent high level ER patient consolidation consolidate block PETHEMA LAL-AR/03 protocol follow allogeneic HSCT . If ER reappear maintenance treatment patient receive allogeneic HSCT , Standby thereof , may administer one two block consolidation LAL -AR -03 protocol . To allow time well characterize LLA thus ensure proper inclusion patient study recommends administer prephase : - Prednisone ( PDN ) 60 mg/m2 po iv characterization LAL maximum 7 day . intrathecal chemotherapy - Methotrexate ( MTX ) : 12 mg - ARA - C : 30 mg - Hydrocortisone 20 mg The LAL meeting inclusion criterion , study may continue Induction chemotherapy - Vincristine ( VCR ) 1.5 mg/m2 ( maximum dose 2 mg ) iv day 1 8 . - daunorubicin ( DNR ) 30 mg/m2 iv day 1 8 . - Prednisone ( PDN ) : 60 mg/m2 night , i.v . p.o , 1-14 day Study bone marrow day +14 - Less 10 % blast ( morphology ) hypocellular bone marrow - Vincristine ( VCR ) 1.5 mg/m2 ( maximum dose 2 mg ) iv 15 22 - daunorubicin ( DNR ) 30 mg/m2 i.v 15 22 - L -asparaginase ( L -ASA ) E. coli ( Kidrolase ® ) : 10,000 IU/m2 , iv , 16-20 , 23-27 . - 1,000 mg/m2 cyclophosphamide , i.v . day 36 - Prednisone ( PDN ) : - 60 mg/m2 per day , i.v p.o , day 15-27 - 30 mg/m2 per day , i.v p.o , day 28-35 - Equal 10 % blast ( morphology ) - Step PETHEMA protocol LAL-AR/2003 Intrathecal chemotherapy - Methotrexate ( MTX ) 12 mg day 1 29 - ARA- C : 30 mg day 1 29 - Hydrocortisone 20 mg day 1 29 Evaluation end induction ( day 28 finding hemoperiférica recovery ) - Patients RC : consolidation -1 - Patients without RC : exclude . Step PETHEMA LAL-AR/2003 protocol . Study ER end induction . Molecular response consider ER &lt; 0.01 % . Although molecular response achieve , patient remain protocol standard response day 14 CR day 28 . Consolidation treatment -1 These cycle include know cytostatics LAL activity intermediate high dos . This phase treatment possible begin two week administration last dose cytostatic induction phase . The patient WBC count &gt; 3x109 / L ( granulocytes &gt; 1.5 x 109 / L ) platelets &gt; 100x109 / L. Mercaptopurine ( MP ) 50 mg/m2 , po , day 1-7 , 28-35 56-63 MTX : 3 g/m2 iv , 24 hour , day 1 , 28 56 . For administration , rescue treatment follow rule specify . VP -16 100 mg/m2 ( infusion 1 hour ) , 14-15 42-43 ARA- C 500 mg/m2 iv every 12 hour , 3 hour , 14-15 42-43 . Intrathecal Chemotherapy Methotrexate ( MTX ) 12 mg day 1 , 28 56 ARA- C : 30 mg day 1 , 28 56 Hydrocortisone 20 mg day 1 , 28 56 Treatment consolidation-2/reinduction It consist cycle similar induction chemotherapy . It start possible within one week completion last dose mercaptopurine previous cycle ( thus , 18th week start treatment ) . Dexamethasone ( DXM ) : 10 mg/m2 per day , p.o i.v 1-14 day 5 mg/m2 night , p.o i.v. , day 15 21 VCR 1.5 mg/m2 , i.v . , day 1 , 8 15 DNR : 30 mg/m2 , i.v . , 1 , 2 , 8 9 CFM 600 mg/m2 day , i.v . , day 1 15 L -ASA E. coli ( Kidrolase ® ) : 10,000 IU/m2 i.m . i.v. , day 1-4 15-18 . Intrathecal Chemotherapy methotrexate ( MTX ) 12 mg day 1 15 ARA- C : 30 mg day 1 15 Hydrocortisone 20 mg day 1 15 Evaluation ER end consolidation A cytofluorometric study fee mo If ER &gt; 0.05 % ( test two separate occasion 15 day ) patient go high-risk protocol ( PETHEMA LAL-AR/2003 ) . If ER &lt; 0.05 % patient continue protocol . Maintenance treatment 1 reinducciones It consist continuous administration chemotherapy ( mercaptopurine methotrexate ) reinducciones year start treatment . It last therefore approximately 22 52 week treatment . Continuous Chemotherapy - MP 50 mg/m2 per day , p.o - MTX 20 mg/m2 per week , i.m . Reinducciones - VCR 1.5 mg/m2 ( maximum dose 2 mg ) , iv , day 1 . - PDN 60 mg/m2 night , i.v . p.o , day 1-7 - L - ASA E. coli ( Kidrolase ® ) : 20,000 IU/m2 i.m . i.v . , day 1 . - Intrathecal Chemotherapy Methotrexate ( MTX ) 12 mg 1st ARA- C : 30 mg 1st Hydrocortisone 20 mg Day 1 During week administration cycle chemotherapy reinduction continuous suspend . Evaluation fourth reinduction . Immunophenotypic study new bone marrow make - If ER &lt; 0.01 % , subsequent reinducciones suspend continue continuous chemotherapy week 52 , point switch maintenance -2 . - If ER 0.05 % 0.01 % , reinducciones 5 administer 8 - If ER &gt; 0.05 % ( test two separate occasion 15 day ) patient go high-risk protocol ( PETHEMA LAL-AR/2003 ) . Treatment Support 2 It consisitirá continuous administration chemotherapy ( mercaptopurine , methotrexate ) complete two year continuous complete remission . - MP 50 mg/m2 per day , p.o - MTX 20 mg/m2 per week , i.m . Throughout maintenance treatment seek retain WBC count 2.5 5x109 / L platelet count 120x109 / L. If low limit reduce decreased 20 % dos MP MTX . If number leukocyte exceed 5x109 / L increase 20 % dose MP ( 50 60 mg/m2 )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Adults ( age &gt; 15 year ) ALL standard risk previously untreated . The LAL standard risk define follow criterion : Age le 30 year WBC &lt; 25x109 / L Absence cytogenetic alteration misbehave forecast ( 9 , 22 ) demonstration BCRABL rearrangement alteration 11q23 , demonstration ALL1AF4 rearrangement ( MLL ) LAL L3 type mature phenotype B ( sIg + ) cytogenetic abnormality characteristic Burkitt LAL ( [ 8 , 14 ] , [ 2 , 8 ] , [ 8 , 22 ] ) . For patient BURKIMAB study . LAL Ph ( BCRABL ) positive . These patient treat imatinib associate chemotherapy . Biphenotypic acute leukemia bilinear . For patient treatment recommend LAM guideline . Acute undifferentiated leukemia . For patient treatment recommend LAM guideline . Patients history coronary artery disease , valvular hypertensive heart disease . Patients chronic liver disease . Patients chronic respiratory failure . Renal failure due LAL . Severe neurological disorder , due LAL . General State concern ( grade 3 4 WHO scale ) , attributable LAL .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>